Recruiting PHASE1 INTERVENTIONAL 1-arm NCT06710717

Autologous CD19 Car T-Cell Therapy For Severe Refractory Systemic Lupus Erythematosus (SLE)

Autologous CD19 Car T-Cell Therapy For Patients With Severe Refractory Systemic Lupus Erythematosus - A Pilot Study

Sponsor: National University of Malaysia

Conditions Systemic Lupus Erythematous (SLE)

Updated 2 times since 2024 Last updated: May 22, 2025 Started: Jan 3, 2025 Primary completion: Dec 2, 2028 Completion: Jan 2, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06710717, this PHASE1 trial focuses on Systemic Lupus Erythematous (SLE) and remains actively recruiting participants. Sponsored by National University of Malaysia, it has been updated 2 times since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

2 versions recorded

Jun 2025 — Present [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Dec 2024 — Jun 2025 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National University of Malaysia
Plutonet Sdn Bhd

Data source: National University of Malaysia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bandar Tun Razak, Malaysia